Oppenheimer analyst Jay Olson raised the firm’s price target on Viking Therapeutics to $20 from $17 and keeps an Outperform rating on the shares. The firm views VK2735 as an underappreciated asset for Viking with a large potential opportunity in obesity. Oppenheimer added that it believes the Phase 1 data for VK2735 expected in Q1 could unlock substantial shareholder value, and its scenario analysis forecasts +20% probability-weighted upside.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
- Viking Therapeutics reports Q4 EPS (26c), consensus (23c)
- Viking Therapeutics options imply 11.2% move in share price post-earnings
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call